268 related articles for article (PubMed ID: 32859926)
1. Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity.
Grabovska Y; Mackay A; O'Hare P; Crosier S; Finetti M; Schwalbe EC; Pickles JC; Fairchild AR; Avery A; Cockle J; Hill R; Lindsey J; Hicks D; Kristiansen M; Chalker J; Anderson J; Hargrave D; Jacques TS; Straathof K; Bailey S; Jones C; Clifford SC; Williamson D
Nat Commun; 2020 Aug; 11(1):4324. PubMed ID: 32859926
[TBL] [Abstract][Full Text] [Related]
2. The unique immune ecosystems in pediatric brain tumors: integrating single-cell and bulk RNA-sequencing.
Cao L; Xie W; Ma W; Zhao H; Wang J; Liang Z; Tian S; Wang B; Ma J
Front Immunol; 2023; 14():1238684. PubMed ID: 38094301
[TBL] [Abstract][Full Text] [Related]
3. EGFR mutation: novel prognostic factor associated with immune infiltration in lower-grade glioma; an exploratory study.
Hao Z; Guo D
BMC Cancer; 2019 Dec; 19(1):1184. PubMed ID: 31801484
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in CNS cancers: the role of immune cell trafficking.
Ratnam NM; Gilbert MR; Giles AJ
Neuro Oncol; 2019 Jan; 21(1):37-46. PubMed ID: 29771386
[TBL] [Abstract][Full Text] [Related]
5. Exploitation of immune mechanisms in the treatment of central nervous system cancer.
Pollack IF; Okada H; Chambers WH
Semin Pediatr Neurol; 2000 Jun; 7(2):131-43. PubMed ID: 10914414
[TBL] [Abstract][Full Text] [Related]
6. DIMEimmune: Robust estimation of infiltrating lymphocytes in CNS tumors from DNA methylation profiles.
Safaei S; Mohme M; Niesen J; Schüller U; Bockmayr M
Oncoimmunology; 2021; 10(1):1932365. PubMed ID: 34235002
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Cacciotti C; Choi J; Alexandrescu S; Zimmerman MA; Cooney TM; Chordas C; Clymer J; Chi S; Yeo KK
J Neurooncol; 2020 Aug; 149(1):113-122. PubMed ID: 32627129
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system.
Adamson DC; Rasheed BA; McLendon RE; Bigner DD
Cancer Biomark; 2010; 9(1-6):193-210. PubMed ID: 22112477
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapeutic approaches for glioma.
Okada H; Kohanbash G; Zhu X; Kastenhuber ER; Hoji A; Ueda R; Fujita M
Crit Rev Immunol; 2009; 29(1):1-42. PubMed ID: 19348609
[TBL] [Abstract][Full Text] [Related]
10. Immunologic Profiling of Mutational and Transcriptional Subgroups in Pediatric and Adult High-Grade Gliomas.
Bockmayr M; Klauschen F; Maire CL; Rutkowski S; Westphal M; Lamszus K; Schüller U; Mohme M
Cancer Immunol Res; 2019 Sep; 7(9):1401-1411. PubMed ID: 31266783
[TBL] [Abstract][Full Text] [Related]
11. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
12. Natural and cryptic peptides dominate the immunopeptidome of atypical teratoid rhabdoid tumors.
Marcu A; Schlosser A; Keupp A; Trautwein N; Johann P; Wölfl M; Lager J; Monoranu CM; Walz JS; Henkel LM; Krauß J; Ebinger M; Schuhmann M; Thomale UW; Pietsch T; Klinker E; Schlegel PG; Oyen F; Reisner Y; Rammensee HG; Eyrich M
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599019
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
[TBL] [Abstract][Full Text] [Related]
14. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
15. Immunological classification of gliomas based on immunogenomic profiling.
Feng Q; Li L; Li M; Wang X
J Neuroinflammation; 2020 Nov; 17(1):360. PubMed ID: 33246490
[TBL] [Abstract][Full Text] [Related]
16. A Toolkit for Profiling the Immune Landscape of Pediatric Central Nervous System Malignancies.
Rozowsky JS; Meesters-Ensing JI; Lammers JAS; Belle ML; Nierkens S; Kranendonk MEG; Kester LA; Calkoen FG; van der Lugt J
Front Immunol; 2022; 13():864423. PubMed ID: 35464481
[TBL] [Abstract][Full Text] [Related]
17. Differentiation of Outcomes by Treatment Regimen and Histology in Central Nervous System Primary Embryonal Tumors.
Bhimani AD; Ryoo JS; Reddy AK; Denyer S; McGuire LS; Alonso M; Mehta AI
World Neurosurg; 2020 Sep; 141():e289-e306. PubMed ID: 32434022
[TBL] [Abstract][Full Text] [Related]
18. Clinical trials in cellular immunotherapy for brain/CNS tumors.
Badhiwala J; Decker WK; Berens ME; Bhardwaj RD
Expert Rev Neurother; 2013 Apr; 13(4):405-24. PubMed ID: 23545055
[TBL] [Abstract][Full Text] [Related]
19. Investigation of white blood cell characteristics in cerebrospinal fluid samples at pediatric brain tumor diagnosis.
Greer HR; Miller K; Samay S; Nellan A; Green AL
J Neurooncol; 2022 Sep; 159(2):301-308. PubMed ID: 35731362
[TBL] [Abstract][Full Text] [Related]
20. The immune contexture of primary central nervous system diffuse large B cell lymphoma associates with patient survival and specific cell signaling.
Alame M; Cornillot E; Cacheux V; Rigau V; Costes-Martineau V; Lacheretz-Szablewski V; Colinge J
Theranostics; 2021; 11(8):3565-3579. PubMed ID: 33664848
[No Abstract] [Full Text] [Related]
[Next] [New Search]
